CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 784.87 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 632.34K shares, a 46.48% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 152.53K shares, a 32.21% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 45.42K shares, a 39.44% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 683.49K shares.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 2.14M shares, a 1793.21% increase from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 112.79K shares, a 66.85% decline from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 340.28K shares, a 302.06% increase from fiscal 2022.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 84.63K shares, a 231.24% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 632.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 784.87K shares 10-Q · filed 2026-08-06 | 830.28K shares derived: sum of 3 quarters · filed 2026-08-06 | 1.51M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 152.53K shares 10-Q · filed 2026-05-07 | 197.95K shares derived: sum of 2 quarters · filed 2026-05-07 | 881.43K shares derived: sum of 3 quarters · filed 2026-05-07 | 2.06M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 45.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 728.90K shares derived: sum of 2 quarters · filed 2026-03-05 | 1.91M shares derived: sum of 3 quarters · filed 2026-03-05 | 2.14M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 683.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.86M shares derived: sum of 2 quarters · filed 2025-11-06 | 2.09M shares 10-Q · filed 2025-11-06 | 2.16M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 1.18M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.41M shares 10-Q · filed 2025-08-12 | 1.48M shares derived: sum of 3 quarters · filed 2025-08-12 | 1.09M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 225.00K shares 10-Q · filed 2025-05-14 | 300.00K shares derived: sum of 2 quarters · filed 2025-05-14 | -90.10K shares derived: sum of 3 quarters · filed 2025-05-14 | 331.69K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 75.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -315.10K shares derived: sum of 2 quarters · filed 2025-03-25 | 106.69K shares derived: sum of 3 quarters · filed 2025-03-25 | 112.79K shares 10-K · filed 2025-03-25 |
| 2024-09-30 | -390.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 31.69K shares derived: sum of 2 quarters · filed 2024-11-12 | 37.79K shares 10-Q · filed 2024-11-12 | 119.66K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 421.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 427.89K shares 10-Q · filed 2024-08-14 | 509.76K shares derived: sum of 3 quarters · filed 2024-08-14 | 514.24K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 6.10K shares 10-Q · filed 2024-05-15 | 87.97K shares derived: sum of 2 quarters · filed 2024-05-15 | 92.45K shares derived: sum of 3 quarters · filed 2024-05-15 | 231.24K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 81.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 86.35K shares derived: sum of 2 quarters · filed 2024-03-28 | 225.14K shares derived: sum of 3 quarters · filed 2024-03-28 | 340.28K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 4.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 143.28K shares derived: sum of 2 quarters · filed 2023-11-14 | 258.42K shares 10-Q · filed 2023-11-14 | 280.40K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 138.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 253.93K shares 10-Q · filed 2023-08-10 | 275.92K shares derived: sum of 3 quarters · filed 2023-08-10 | 325.57K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 115.14K shares 10-Q · filed 2023-05-11 | 137.13K shares derived: sum of 2 quarters · filed 2023-05-11 | 186.77K shares derived: sum of 3 quarters · filed 2023-05-11 | 199.77K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 21.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 71.63K shares derived: sum of 2 quarters · filed 2023-03-06 | 84.63K shares derived: sum of 3 quarters · filed 2023-03-06 | 84.63K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 49.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 62.65K shares derived: sum of 2 quarters · filed 2022-11-14 | 62.65K shares 10-Q · filed 2022-11-14 | 62.65K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 13.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 13.00K shares 10-Q · filed 2022-08-15 | 13.00K shares derived: sum of 3 quarters · filed 2022-08-15 | 29.18K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-16 | 0.00 shares derived: sum of 2 quarters · filed 2022-05-16 | 16.18K shares derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 16.18K shares derived: sum of 2 quarters · filed 2022-03-07 | 25.55K shares 10-K · filed 2022-03-07 | |
| 2021-09-30 | 16.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 25.55K shares 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | 9.38K shares 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |